Is Inhibrx Biosciences, Inc. (NASDAQ:INBX) a buy in 2026?
Hold. Inhibrx Biosciences, Inc. is a wait-and-watch at today's price, not a fresh buy.
Binary biotech bet on INBRX-109 in chondrosarcoma — compelling science, but $940M market cap prices in significant clinical success already.
Where INBX is headed
By late 2027, Inhibrx Biosciences will either be approaching a pivotal regulatory milestone for INBRX-109 in chondrosarcoma — a disease with zero approved systemic therapies and massive unmet need — or facing the existential reckoning that every single-asset clinical-stage biotech eventually confronts. The company's entire valuation thesis rests on DR5-targeting biology in a rare cancer where even modest efficacy data could support accelerated approval. If Phase 2/pivotal data reads out favorably, INBX could be a $3-5B takeout target or command a $2B+ independent valuation as it approaches filing. The OX40 agonist INBRX-106 provides optionality but is far earlier and in a crowded immuno-oncology space.
Read the full Compass Direction on INBX
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $89.10).
See the full INBX analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Inhibrx Biosciences, Inc. (NASDAQ:INBX) a buy in 2026?
Hold. Inhibrx Biosciences, Inc. is a wait-and-watch at today's price, not a fresh buy. Binary biotech bet on INBRX-109 in chondrosarcoma — compelling science, but $940M market cap prices in significant clinical success already.
What is INBX's Compass Score?
Inhibrx Biosciences, Inc. scores 42/100 on Alexandria's Compass, placing it in the "Neutral" tier. Scores blend eight factors and update weekly.
What is the price target for INBX?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the INBX page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.